Gynecologic Oncology Group

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

CollaboratorPhase 3Recruiting20261,023 people14 Oct 2025clinicaltrials.gov

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

CollaboratorPhase 3Recruiting2025770 people13 Feb 2025clinicaltrials.gov

NCT06486441

CollaboratorPhase 3Active, not recruiting2024640 people3 Jul 2024clinicaltrials.gov

NCT06132958

CollaboratorPhase 3Active, not recruiting2023710 people15 Nov 2023clinicaltrials.gov

NCT05659381

Phase 3Recruiting2024220 people21 Dec 2022clinicaltrials.gov

NCT05201001

CollaboratorPhase 2Withdrawn20230 people21 Jan 2022clinicaltrials.gov

NCT05173987

CollaboratorPhase 3Active, not recruiting2022280 people30 Dec 2021clinicaltrials.gov

NCT04634877

CollaboratorPhase 3Active, not recruiting2021990 people18 Nov 2020clinicaltrials.gov

NCT04221945

CollaboratorPhase 3Completed20201,060 people9 Jan 2020clinicaltrials.gov

NCT03556839

CollaboratorPhase 3Completed2018410 people14 Jun 2018clinicaltrials.gov

NCT02432365

CollaboratorPhase 2Status unknown201564 people4 May 2015clinicaltrials.gov

NCT02228681

Phase 2Completed201574 people29 Aug 2014clinicaltrials.gov

NCT02065687

Phase 2/3Status unknown2014469 people19 Feb 2014clinicaltrials.gov

NCT01595061

Phase 2Status unknown201257 people9 May 2012clinicaltrials.gov

NCT01533207

Phase 3Terminated201238 people15 Feb 2012clinicaltrials.gov

NCT01414608

Phase 3Completed2012926 people11 Aug 2011clinicaltrials.gov

NCT01295502

Phase 1Status unknown201145 people14 Feb 2011clinicaltrials.gov

NCT01101451

Phase 3Completed2010340 people12 Apr 2010clinicaltrials.gov

NCT01042522

Phase 2Status unknown201063 people5 Jan 2010clinicaltrials.gov

NCT00942357

Phase 3Status unknown2009813 people20 Jul 2009clinicaltrials.gov